Circulating and Tissue lncRNAs CASC2 and TUG1 as Prognostic Biomarkers in HCV-Associated Hepatocellular Carcinoma

Authors

  • Nahla Ibrahim Elattar, Hanan samir Ahmed, Ola Elsayed Abdel Latif Elnaggar, Nahla Elsayed Elgammal

Keywords:

lncRNAs, CASC2, TUG1 , HCV-Associated Hepatocellular Carcinoma

Abstract

Background: Hepatocellular carcinoma (HCC) arising in the setting of chronic hepatitis C virus (HCV) infection ischaracterized by marked biological heterogeneity and highly variable clinical outcomes. Despite advances in antiviraltherapy and improvements in locoregional and systemic treatments, prognosis remains poor for many patients due to high rates of tumor recurrence, vascular invasion,

Downloads

Download data is not yet available.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273.

Downloads

Published

2024-03-15

How to Cite

Nahla Ibrahim Elattar, Hanan samir Ahmed, Ola Elsayed Abdel Latif Elnaggar, Nahla Elsayed Elgammal. (2024). Circulating and Tissue lncRNAs CASC2 and TUG1 as Prognostic Biomarkers in HCV-Associated Hepatocellular Carcinoma . Pegem Journal of Education and Instruction, 14(3), 916–929. Retrieved from https://pegegog.net/index.php/pegegog/article/view/4865

Issue

Section

Article